Achieving Equity in Alzheimer's Disease
As Alzheimer’s therapies continue to make great progress, questions remain about how we can ensure equitable access to the right treatments, for the right patients, at the right time. What do we know--and not know--about the etiology of the disease in and the impact of new treatments on minoritized, and especially Black, populations? Key Question: How do we achieve success with such low rates of racial and ancestral diversity in clinical trials?
Disrupting Brain Health Through Technology: The Hope, the Challenge, the Future
Technology and data hold great promise for ending Alzheimer’s—from tailored prevention to detection, diagnosis, and precision treatments. Of course, these technologies will be meaningless to historically underserved or marginalized groups if they are developed without diverse populations in mind. This session will explore how technology and data are deepening our understanding of Alzheimer’s disease and what needs to be done to ensure it is inclusive and accessible to all.
